In Vitro Diagnostic Device Designed for Dried Blood Spot Analysis
MILFORD, Mass.--(BUSINESS WIRE)--Oct. 10, 2018--
Waters Corporation (NYSE:WAT) introduced the RenataDX™
Screening System, a flow-injection tandem mass spectrometry
(FIA-MS/MS) system for rapid high-throughput analysis of extracted dried
blood spots and other human biological matrices.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20181010005051/en/
Waters New RenataDX Screening System Delivers Fast, Accurate Results for Clinical Scientists (Photo: Business Wire)
“Waters has long been a trusted specialty measurement partner for mass
spectrometry in the clinical laboratory. Continuing that history of
purposeful innovation, the RenataDX Screening System is designed to
ensure ease of use in clinical situations where system performance is
critical to accurate analysis of biological samples,” said Andy Qiu,
General Manager, Global Clinical Diagnostics Business at Waters.
The need for dried blood spot analysis in clinical laboratories is
growing annually. Scientists require more sample throughput capabilities
to meet this demand. The bench-top system builds on the robustness and
reliability that scientists have come to expect from Waters, allowing
them to have the highest level of confidence in their results.
The RenataDX Screening System also offers the flexibility laboratories
require to adjust to their needs. With the ability to run any suitable
FIA-MS/MS laboratory developed test or ready to use reagent kit,
scientists are not locked in to a prescriptive workflow. It incorporates
the high-performance combination of the Xevo™ TQD IVD Mass Spectrometer,
the ACQUITY™ UPLC™ I-Class IVD Binary Solvent Manager, and the 3777C IVD
Sample Manager.
Driven by the combination of MassLynx (IVD) and IonLynx™ Application
Manager Software, data is streamlined and seamlessly integrated into
laboratory workflows, allowing scientists to get their data in real
time. The IonLynx Application Manager leverages Waters’ twenty years of
experience processing FIA-MS/MS data, to present clinical scientists
with a familiar, yet robust and reliable diagnostically-proven
informatics tool.
The RenataDX Screening System is manufactured as an U.S. FDA Class I
medical device and is CE Marked to the European Directive 98/79/EC
(IVDD).
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE: WAT), the world's leading specialty
measurement company, has pioneered chromatography, mass spectrometry,
and thermal analysis innovations serving the life, materials, and food
sciences for nearly 60 years. With approximately 7,000 employees
worldwide, Waters operates directly in 31 countries, including 15
manufacturing facilities, and with products available in more than 100
countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181010005051/en/
Source: Waters Corporation
Waters Corporation
Chris Orlando, 508-482-2623
Senior Public
Relations Manager
Chris_Orlando@waters.com